These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 1760877)
1. Growth factor and oncogene signalling pathways as targets for rational anticancer drug development. Powis G; Kozikowski A Clin Biochem; 1991 Oct; 24(5):385-97. PubMed ID: 1760877 [TBL] [Abstract][Full Text] [Related]
2. Drugs active against growth factor and oncogene phosphatidylinositol signalling pathways. Powis G Semin Cancer Biol; 1992 Dec; 3(6):343-50. PubMed ID: 1286155 [TBL] [Abstract][Full Text] [Related]
3. D-3-deoxy-3-substituted myo-inositol analogues as inhibitors of cell growth. Powis G; Aksoy IA; Melder DC; Aksoy S; Eichinger H; Fauq AH; Kozikowski AP Cancer Chemother Pharmacol; 1991; 29(2):95-104. PubMed ID: 1760864 [TBL] [Abstract][Full Text] [Related]
4. Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251. Andrejauskas-Buchdunger E; Regenass U Cancer Res; 1992 Oct; 52(19):5353-8. PubMed ID: 1394140 [TBL] [Abstract][Full Text] [Related]
5. Signalling targets for anticancer drug development. Powis G Trends Pharmacol Sci; 1991 May; 12(5):188-94. PubMed ID: 1862534 [TBL] [Abstract][Full Text] [Related]
6. Advances with phospholipid signalling as a target for anticancer drug development. Powis G; Berggren M; Gallegos A; Frew T; Hill S; Kozikowski A; Bonjouklian R; Zalkow L; Abraham R; Ashendel C Acta Biochim Pol; 1995; 42(4):395-403. PubMed ID: 8852330 [TBL] [Abstract][Full Text] [Related]
7. Signalling pathways as targets for anticancer drug development. Powis G Pharmacol Ther; 1994; 62(1-2):57-95. PubMed ID: 7991648 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of growth factor-dependent inositol phosphate Ca2+ signaling by antitumor ether lipid analogues. Seewald MJ; Olsen RA; Sehgal I; Melder DC; Modest EJ; Powis G Cancer Res; 1990 Aug; 50(15):4458-63. PubMed ID: 2369723 [TBL] [Abstract][Full Text] [Related]
9. Inhibitors of phosphatidylinositol signalling as antiproliferative agents. Powis G; Phil D Cancer Metastasis Rev; 1994 Mar; 13(1):91-103. PubMed ID: 8143348 [TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Buchdunger E; Zimmermann J; Mett H; Meyer T; Müller M; Regenass U; Lydon NB Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2558-62. PubMed ID: 7708684 [TBL] [Abstract][Full Text] [Related]
12. Platelet-activating factor stimulation of tyrosine kinase and its relationship to phospholipase C in rabbit platelets: studies with genistein and monoclonal antibody to phosphotyrosine. Dhar A; Paul AK; Shukla SD Mol Pharmacol; 1990 Apr; 37(4):519-25. PubMed ID: 1691437 [TBL] [Abstract][Full Text] [Related]
13. Inhibitors of phospholipid intracellular signaling as antiproliferative agents. Powis G; Hill SR; Frew TJ; Sherrill KW Med Res Rev; 1995 Mar; 15(2):121-38. PubMed ID: 7739293 [TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Raymond E; Faivre S; Armand JP Drugs; 2000; 60 Suppl 1():15-23; discussion 41-2. PubMed ID: 11129168 [TBL] [Abstract][Full Text] [Related]
15. Inositol lipids and phosphates in the regulation of the growth and differentiation of haemopoietic and other cells. Michell RH; Conroy LA; Finney M; French PJ; Brown G; Creba JA; Bunce CM; Lord JM Philos Trans R Soc Lond B Biol Sci; 1990 Mar; 327(1239):193-207. PubMed ID: 1969659 [TBL] [Abstract][Full Text] [Related]
16. Effects of anti-7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene on human small airway epithelial cells and the protective effects of myo-inositol. Jyonouchi H; Sun S; Iijima K; Wang M; Hecht SS Carcinogenesis; 1999 Jan; 20(1):139-45. PubMed ID: 9934861 [TBL] [Abstract][Full Text] [Related]
17. Growth factors, oncogenes and inositol lipids. Berridge MJ Cancer Surv; 1986; 5(2):413-30. PubMed ID: 3779662 [TBL] [Abstract][Full Text] [Related]
18. Multiple effects of staurosporine, a kinase inhibitor, on thymocyte functions. Comparison with the effect of tyrosine kinase inhibitors. Zilberman Y; Gutman Y Biochem Pharmacol; 1992 Oct; 44(8):1563-8. PubMed ID: 1417980 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor. Dahring TK; Lu GH; Hamby JM; Batley BL; Kraker AJ; Panek RL J Pharmacol Exp Ther; 1997 Jun; 281(3):1446-56. PubMed ID: 9190882 [TBL] [Abstract][Full Text] [Related]
20. A strategy for screening anti-tumor drugs utilizing oncogenes encoded in retroviral vectors. Corbley MJ; Cherington V; Traxler PM; Lydon NB; Roberts TM Int J Cancer; 1996 Jun; 66(6):753-9. PubMed ID: 8647645 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]